EVFM - Earnings announcements

-- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter -- -- Delivered $1.0 Million of Operating Income in Q3 2025 -- SAN DIEGO, Nov. 13, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and nine-month periods ended September 30, 2025 and provided a business update. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Sales rebounded in the thi

— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,

— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Received $1 million from Aditxt, Inc. (NASDAQ:ADTX) in May 2024 in consideration for reinstating and amending

— On track to achieve third consecutive year of revenue growth – — Third consecutive quarter of favorable sales and marketing expense as a percentage of net sales — — Reduced loss from operations by 81% vs. Q3 2022 — SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> $5.1 million in net product sales of Phexxi® (la

— On track to achieve third consecutive year of revenue growth – — Second consecutive quarter of favorable net product sales to sales and marketing expense ratio — — Reduced total operating expenses 68% — — Decreased loss from operations by 70% — SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2023. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "This marks the second consecutive quarter in which our

-- Increased net product revenue 37% in the first quarter of 2023 vs. prior year quarter -- -- Reduced operating expenses 72% -- -- Decreased loss from operations by 88% -- -- Reaffirms path to positive EBITDA -- SAN DIEGO, June 16, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFMD) today announced financial results for the first quarter of 2023, including growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO, Aug. 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Date: Thursday, August 11, 2022 Time: 5:00 p.m. ET (2:00 p.m. PT) Live call: (877) 445-9755 (U.S. toll-free) or (201) 493-6744 Webcast (live and archived): https://evofem.investorroom.com/Update or https://www.webcast-eqs.com/register/evofem2022811/en Please connect to the webcast at least 15 min

-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO, July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Date: Thursday, August 4, 2022 Time: 5:00 pm. ET (2:00pm. PT) Live call: (800) 285-6670 (U.S. toll-free) or (713) 481-1320 Webcast (live and archived) and related slide presentation:

-- Double digit growth in net revenues over Q4 2021 -- -- Reduced selling and marketing costs 49% and total operating expense 19% vs. Q4 2021 -- -- Decreased loss from operations for the third consecutive quarter -- -- On track to report top-line Phase 3 data for the prevention of chlamydia and gonorrhea in 2H 2022 -- -- Conference call scheduled for 4:30 p.m. ET Today -- SAN DIEGO, May 4, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) ("Evofem" or the "Company"), today reported financial results for the three-month period ended March 31, 2022. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Bioscien

-- Conference Call Scheduled for 4:30 p.m. ET – SAN DIEGO, April 25, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the first quarter ended March 31, 2022 as follows: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Date: Wednesday, May 4, 2022 Time: 4:30 p.m. ET (1:30 p.m. PT) Live call: (877) 407-0890 (U.S. toll-free) or (201) 389-0918 Webcast (live and archived) and related slide presentati

SAN DIEGO, March 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a commercial stage biopharmaceutical company, today reported financial results for the three- and twelve-month periods ended December 31, 2021. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "In our first full year as a commercial company Evofem delivered strong growth, capped by an exceptional fourth quarter," said Saundra Pelletier, Chief Executive Officer. "Additionally, we achieved a significant milestone today: we comp

SAN DIEGO, Feb. 17, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2021 on Thursday, March 3, 2022 at 4:30 p.m. ET (1:30 p.m. PT). EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> The webcast (live and archived) and related slide presentation can be accessed through https://evofem.investorroom.com/2021Q4YEResults or directly at https://edge.media-se

SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine-month periods ended September 30, 2021. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "We are extremely excited by the initial results of our celebrity DTC campaign, which is driving an increase in awareness of Phexxi among our target audience and substantial growth in prescriptions filled," said Saundra Pelletier, Evofem's Chief Executi

SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the third quarter ended September 30, 2021 on Monday, November 15, 2021 at 4:30 p.m. ET (1:30 p.m. PT). EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> The webcast (live and archived) and related slide presentation can be accessed through https://evofem.investorroom.com/2021Q3Results or directly at https://edge.media-server.com/

SAN DIEGO, Aug. 11, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and six-month periods ended June 30, 2021. "We are pleased to show strong and sustainable growth in Phexxi prescriptions and dispensed units in the second quarter. This momentum allows us to further accelerate the growth trajectory with our celebrity campaign launching in early September," said Saundra Pelletier, Evofem's Chief Executive Officer. Second quarter and recent highlights include: 12,763 Phexxi® (lactic acid, c

SAN DIEGO, July 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 at 4:30 p.m. ET (1:30 p.m. PT). The webcast (live and archived) and related slide presentation can be accessed through https://evofem.investorroom.com/2021Q2Results or directly at https://edge.media-server.com/mmc/p/h6zpy9h5. Please connect to the webcast at least 15 minutes prior to the start of the call to download any software tha